ROSEMARY SON: Open Payments
NPI 1609190503 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,305 in 45 payments from 13 companies in 2025. Trend: 2023 $4,044 · 2024 $6,069 · 2025 $7,305
Food & beverage: $2,964Consulting: $2,296Speaker / faculty: $1,910Travel & lodging: $135
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $2,603 |
| Novartis Pharmaceuticals Corporation | 5 | $1,669 |
| LEO Pharma Inc. | 5 | $1,173 |
| Amgen Inc. | 6 | $599 |
| Janssen Scientific Affairs, LLC | 3 | $278 |
| UCB, Inc. | 3 | $247 |
| Lilly USA, LLC | 3 | $216 |
| Incyte Corporation | 3 | $159 |
| Arcutis Biotherapeutics, Inc. | 2 | $146 |
| ABBVIE INC. | 3 | $102 |
Products named: DUPIXENT, COSENTYX, ANZUPGO, OTEZLA, TREMFYA, Bimzelx, EBGLYSS, ADBRY.
Industry payments across TX — which companies pay providers there.
